{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T22:27:13Z","timestamp":1789165633560,"version":"build-2803163510"},"posted":{"date-parts":[[2025,9,26]]},"group-title":"In Review","reference-count":40,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,8,8]]},"abstract":"<title>Abstract<\/title>\n        <p>INTRODUCTION: This study explores the diagnostic accuracy of different biomarkers for Alzheimer\u2019s disease (AD) using data from the Alzheimer's Disease Neuroimaging Initiative (ADNI).METHODS: A cross-sectional analysis was performed on individuals with mild cognitive impairment. Key biomarkers assessed included plasma p-tau217, CSF p-tau181, CSF A\u03b242, and amyloid PET imaging, alongside clinical assessments using the Clinical Dementia Rating (CDR) and the Alzheimer's Disease Assessment Scale (ADAS).RESULTS: Plasma p-tau217 showed the strongest correlation with amyloid-\u03b2 deposition and clinical scores (Adjusted R\u00b2 = 0.53 for ADAS, 0.51 for CDR), outperforming CSF A\u03b242 and CSF p-tau181.DISCUSSION: These results suggest that plasma p-tau217 may serve as a more accurate, cost-effective, and non-invasive alternative to CSF biomarkers and PET imaging. Its superior predictive power highlights its potential in routine clinical settings for early diagnosis and monitoring of AD progression, addressing key challenges in accessibility and patient compliance associated with current diagnostic methods.<\/p>","DOI":"10.21203\/rs.3.rs-7327653\/v1","type":"posted-content","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T11:45:51Z","timestamp":1758887151000},"source":"Crossref","is-referenced-by-count":1,"title":["Comparing the predictive value of plasma p-tau217 and CSF biomarkers (p-tau181, A\u03b242) using amyloid positron emission tomography in Alzheimer's continuum"],"prefix":"10.21203","author":[{"given":"Mohammad Hossein","family":"Azaraein","sequence":"first","affiliation":[{"name":"Shahid Sadoughi University of Medical Sciences and Health Services"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elham","family":"Zarrazvand","sequence":"additional","affiliation":[{"name":"Tehran University of Medical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Heydari","sequence":"additional","affiliation":[{"name":"Qom Islamic Azad University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasim","family":"Asimi","sequence":"additional","affiliation":[{"name":"Islamic Azad University, Tehran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elham","family":"Ramezannezhad","sequence":"additional","affiliation":[{"name":"Isfahan University of Medical Science"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deniz","family":"Rahimipour","sequence":"additional","affiliation":[{"name":"Iran University of Medical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimia","family":"Janeshin","sequence":"additional","affiliation":[{"name":"Shahid Beheshti University of Medical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aida","family":"Mahdian","sequence":"additional","affiliation":[{"name":"Kashan University of Medical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam Fallahpour","family":"Sichani","sequence":"additional","affiliation":[{"name":"Islamic Azad University, Tehran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaghayegh","family":"Farhadi","sequence":"additional","affiliation":[{"name":"Islamic Azad University Sanandaj Branch"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razieh","family":"Zamiri","sequence":"additional","affiliation":[{"name":"University of Padua"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Amir","family":"Amirian","sequence":"additional","affiliation":[{"name":"Kashan University of Medical Sciences and Health Services"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Bemanalizadeh","sequence":"additional","affiliation":[{"name":"NeuroTRACT Association, Tehran University of Medical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/aps.2017.28","author":"Chen GF","year":"2017","unstructured":"Chen, G. F. et al. Amyloid beta: structure, biology and structure-based therapeutic development. Acta Pharmacol Sin. ;38(9):1205-35, Available at: 10.1038\/aps.2017.28. (2017). Available at: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28713158"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1202753","author":"Bateman RJ","year":"2012","unstructured":"Bateman, R. J. et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. ;367(9):795\u2013804, Available at: 10.1056\/NEJMoa1202753. (2012). Available at: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22784036"},{"key":"ref3","author":"Sperling RA","year":"2011","unstructured":"Sperling, R. A. et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. ;7(3):280\u2009\u2013\u200992, doi:10.1016\/j.jalz.2011.03.003. (2011). Available at: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21514248"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/jnc.12202","author":"Gu L","year":"2013","unstructured":"Gu, L. & Guo, Z. Alzheimer's Abeta42 and Abeta40 peptides form interlaced amyloid fibrils. J Neurochem. ;126(3):305\u2009\u2013\u200911, Available at: 10.1111\/jnc.12202. (2013). Available at: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23406382"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/ph17020217","author":"Andersen ABA","year":"2024","unstructured":"Andersen, A. B. A. et al. Multicenter Experience with Good Manufacturing Practice Production of [(11)C]PiB for Amyloid Positron Emission Tomography Imaging. Pharmaceuticals (Basel). ;17(2), Available at: 10.3390\/ph17020217. (2024). Available at: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/38399432"},{"key":"ref6","author":"D'Amico F","year":"2024","unstructured":"D'Amico, F. et al. Standard Procedures and Semiquantification. Methods Mol Biol. ;2785:165\u2009\u2013\u200975, doi:10.1007\/978-1-0716-3774-6_11. (2024). Available at: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/38427194"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci11020215","author":"McGrowder DA","year":"2021","unstructured":"McGrowder, D. A. et al. Cerebrospinal Fluid Biomarkers of Alzheimer's Disease: Current Evidence and Future Perspectives. Brain Sci. ;11(2), Available at: 10.3390\/brainsci11020215. (2021). Available at: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/33578866"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.101030","author":"Martino-Adami PV","year":"2024","unstructured":"Martino-Adami, P. V. et al. Prognostic value of Alzheimer's disease plasma biomarkers in the oldest-old: a prospective primary care-based study. Lancet Reg Health Eur. ;45:101030, Available at: 10.1016\/j.lanepe.2024.101030. (2024). Available at: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/39253733"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23746-0","author":"Cullen NC","year":"2021","unstructured":"Cullen, N. C. et al. Plasma biomarkers of Alzheimer's disease improve prediction of cognitive decline in cognitively unimpaired elderly populations. Nat Commun. ;12(1):3555, Available at: 10.1038\/s41467-021-23746-0. (2021). Available at: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34117234"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2023-1434","author":"Arslan B","year":"2024","unstructured":"Arslan, B., Zetterberg, H. & Ashton, N. J. Blood-based biomarkers in Alzheimer's disease - moving towards a new era of diagnostics. Clin Chem Lab Med. ;62(6):1063-9, Available at: 10.1515\/cclm-2023-1434. (2024). Available at: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/38253262"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23158598","author":"Dulewicz M","year":"2022","unstructured":"Dulewicz, M. et al. Biomarkers for the Diagnosis of Alzheimer's Disease in Clinical Practice: The Role of CSF Biomarkers during the Evolution of Diagnostic Criteria. Int J Mol Sci. ;23(15), Available at: 10.3390\/ijms23158598. (2022). Available at: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/35955728"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcad057","author":"Jonaitis EM","year":"2023","unstructured":"Jonaitis, E. M. et al. Plasma phosphorylated tau 217 in preclinical Alzheimer's disease. Brain Commun. ;5(2):fcad057, Available at: 10.1093\/braincomms\/fcad057. (2023). Available at: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/37013174"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13026","author":"Therriault J","year":"2023","unstructured":"Therriault, J. et al. Equivalence of plasma p-tau217 with cerebrospinal fluid in the diagnosis of Alzheimer's disease. Alzheimers Dement. ;19(11):4967-77, Available at: 10.1002\/alz.13026. (2023). Available at: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/37078495"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1101\/2023.07.11.23292493","author":"Ashton NJ","year":"2023","unstructured":"Ashton, N. J. et al. Diagnostic accuracy of the plasma ALZpath pTau217 immunoassay to identify Alzheimer's disease pathology. medRxiv. Available at: 10.1101\/2023.07.11.23292493. (2023). Available at: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/37502842"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181cb3e25","author":"Petersen RC","year":"2010","unstructured":"Petersen, R. C. et al. Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology. ;74(3):201-9, Available at: 10.1212\/WNL.0b013e3181cb3e25. (2010). Available at: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20042704"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.617173","author":"Xie Y","year":"2020","unstructured":"Xie, Y. et al. Exploring the Pattern Associated With Longitudinal Changes of beta-Amyloid Deposition During Cognitively Normal Healthy Aging. Front Med (Lausanne). ;7:617173, Available at: 10.3389\/fmed.2020.617173. (2020). Available at: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/33585514"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.43.11.2412-a","author":"Morris JC","year":"1993","unstructured":"Morris, J. C. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. ;43(11):2412-4, Available at: 10.1212\/wnl.43.11.2412-a. (1993). Available at: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/8232972"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.140.6.566","author":"Hughes CP","year":"1982","unstructured":"Hughes, C. P., Berg, L., Danziger, W. L., Coben, L. A. & Martin, R. L. A new clinical scale for the staging of dementia. Br J Psychiatry. ;140:566\u2009\u2013\u200972, Available at: 10.1192\/bjp.140.6.566. (1982). Available at: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/7104545"},{"key":"ref19","first-page":"448","article-title":"The Alzheimer's Disease Assessment Scale; An instrument for assessing treatment efficacy","volume":"19","author":"Rc M","year":"1983","unstructured":"Rc, M. The Alzheimer's Disease Assessment Scale; An instrument for assessing treatment efficacy. Psychopharmacol. Bull. 19, 448\u2013450 (1983).","journal-title":"Psychopharmacol. Bull."},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.141.11.1356","author":"Rosen WG","year":"1984","unstructured":"Rosen, W. G., Mohs, R. C. & Davis, K. L. A new rating scale for Alzheimer's disease. Am J Psychiatry. ;141(11):1356-64, Available at: 10.1176\/ajp.141.11.1356. (1984). Available at: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/6496779"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12226","author":"Weber CJ","year":"2021","unstructured":"Weber, C. J. et al. The Worldwide Alzheimer's Disease Neuroimaging Initiative: ADNI-3 updates and global perspectives. Alzheimers Dement (N Y). ;7(1):e12226, Available at: 10.1002\/trc2.12226. (2021). Available at: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/35005206"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201911170","author":"Palmqvist S","year":"2019","unstructured":"Palmqvist, S. et al. Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease. EMBO Mol Med. ;11(12):e11170, Available at: 10.15252\/emmm.201911170. (2019). Available at: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31709776"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24719","author":"Vlassenko AG","year":"2016","unstructured":"Vlassenko, A. G. et al. Imaging and cerebrospinal fluid biomarkers in early preclinical alzheimer disease. Ann Neurol. ;80(3):379\u2009\u2013\u200987, Available at: 10.1002\/ana.24719. (2016). Available at: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27398953"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/aww015","author":"Palmqvist S","year":"2016","unstructured":"Palmqvist, S., Mattsson, N., Hansson, O. & Alzheimer's Disease Neuroimaging, I. Cerebrospinal fluid analysis detects cerebral amyloid-beta accumulation earlier than positron emission tomography. Brain. ;139(Pt 4):1226-36, Available at: 10.1093\/brain\/aww015. (2016). Available at: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26936941"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.archger.2024.105703","author":"Nasiri H","year":"2025","unstructured":"Nasiri, H. et al. The polygenic hazard score mediates the association between plasma neurofilament light chain and brain morphometry in dementia spectrum. Arch Gerontol Geriatr. ;130:105703, Available at: 10.1016\/j.archger.2024.105703. (2025). Available at: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/39631103"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-019-0485-0","author":"Hansson O","year":"2019","unstructured":"Hansson, O., Lehmann, S., Otto, M., Zetterberg, H. & Lewczuk, P. Advantages and disadvantages of the use of the CSF Amyloid beta (Abeta) 42\/40 ratio in the diagnosis of Alzheimer's Disease. Alzheimers Res Ther. ;11(1):34, Available at: 10.1186\/s13195-019-0485-0. (2019). Available at: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31010420"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awv181","author":"Skillback T","year":"2015","unstructured":"Skillback, T. et al. Cerebrospinal fluid tau and amyloid-beta1-42 in patients with dementia. Brain. ;138(Pt 9):2716-31, Available at: 10.1093\/brain\/awv181. (2015). Available at: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26133663"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0781-z","author":"Barthelemy NR","year":"2020","unstructured":"Barthelemy, N. R. et al. A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease. Nat Med. ;26(3):398\u2013407, Available at: 10.1038\/s41591-020-0781-z. (2020). Available at: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32161412"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12081836","author":"Lai R","year":"2024","unstructured":"Lai, R., Li, B. & Bishnoi, R. P-tau217 as a Reliable Blood-Based Marker of Alzheimer's Disease. Biomedicines. ;12(8), Available at: 10.3390\/biomedicines12081836. (2024). Available at: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/39200300"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2022.5272","author":"Mattsson-Carlgren N","year":"2023","unstructured":"Mattsson-Carlgren, N. et al. Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers. JAMA Neurol. ;80(4):360-9, Available at: 10.1001\/jamaneurol.2022.5272. (2023). Available at: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/36745413"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01822-2","author":"Mielke MM","year":"2022","unstructured":"Mielke, M. M. et al. Performance of plasma phosphorylated tau 181 and 217 in the community. Nat Med. ;28(7):1398\u2009\u2013\u2009405, Available at: 10.1038\/s41591-022-01822-2. (2022). Available at: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/35618838"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31823ed0f0","author":"Schoonenboom NS","year":"2012","unstructured":"Schoonenboom, N. S. et al. Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort. Neurology. ;78(1):47\u201354, Available at: 10.1212\/WNL.0b013e31823ed0f0. (2012). Available at: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22170879"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1038\/s43587-023-00471-5","author":"Brum WS","year":"2023","unstructured":"Brum, W. S. et al. A two-step workflow based on plasma p-tau217 to screen for amyloid beta positivity with further confirmatory testing only in uncertain cases. Nat Aging. ;3(9):1079-90, Available at: 10.1038\/s43587-023-00471-5. (2023). Available at: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/37653254"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2015.00138","author":"Struyfs H","year":"2015","unstructured":"Struyfs, H. et al. Cerebrospinal Fluid P-Tau181P: Biomarker for Improved Differential Dementia Diagnosis. Front Neurol. ;6:138, Available at: 10.3389\/fneur.2015.00138. (2015). Available at: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26136723"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2014.12.006","author":"Ewers M","year":"2015","unstructured":"Ewers, M. et al. CSF biomarkers for the differential diagnosis of Alzheimer's disease: A large-scale international multicenter study. Alzheimers Dement. ;11(11):1306-15, Available at: 10.1016\/j.jalz.2014.12.006. (2015). Available at: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25804998"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-022-01005-8","author":"Groot C","year":"2022","unstructured":"Groot, C. et al. Diagnostic and prognostic performance to detect Alzheimer's disease and clinical progression of a novel assay for plasma p-tau217. Alzheimers Res Ther. ;14(1):67, Available at: 10.1186\/s13195-022-01005-8. (2022). Available at: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/35568889"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awac333","author":"Janelidze S","year":"2023","unstructured":"Janelidze, S. et al. Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer's disease. Brain. ;146(4):1592\u2009\u2013\u2009601, Available at: 10.1093\/brain\/awac333. (2023). Available at: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/36087307"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.942629","author":"Chen L","year":"2022","unstructured":"Chen, L. et al. Plasma tau proteins for the diagnosis of mild cognitive impairment and Alzheimer's disease: A systematic review and meta-analysis. Front Aging Neurosci. ;14:942629, Available at: 10.3389\/fnagi.2022.942629. (2022). Available at: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/35959295"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2021.07.007","author":"Qu Y","year":"2021","unstructured":"Qu, Y. et al. Blood biomarkers for the diagnosis of amnestic mild cognitive impairment and Alzheimer's disease: A systematic review and meta-analysis. Neurosci Biobehav Rev. ;128:479\u2009\u2013\u200986, Available at: 10.1016\/j.neubiorev.2021.07.007. (2021). Available at: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34245759"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awaa286","author":"Mattsson-Carlgren N","year":"2020","unstructured":"Mattsson-Carlgren, N. et al. Longitudinal plasma p-tau217 is increased in early stages of Alzheimer's disease. Brain. ;143(11):3234-41, Available at: 10.1093\/brain\/awaa286. (2020). Available at: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/33068398"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-7327653\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-7327653\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T07:54:34Z","timestamp":1760514874000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-7327653\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":40,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-7327653\/v1","relation":{},"subject":[],"published":{"date-parts":[[2025,9,26]]},"subtype":"preprint"}}